FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sonia Davis

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Double-Blind Method

Activities & Behaviors

Co-author Network

Publications

TOP 3
Jonathan M Meyer; Joseph P McEvoy; Vicki G Davis; Donald C Goff; Henry A Nasrallah; Sonia M Davis; John K Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
David L Penn; Richard S E Keefe; Sonia M Davis; Piper S Meyer; Diana O Perkins; Diane Losardo; Jeffrey A Lieberman
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
Robert A Rosenheck; Vicki G Davis; Sonia M Davis; Scott Stroup; Joseph McEvoy; Marvin Swartz; Jeffrey Lieberman
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sonia Davis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Jonathan M Meyer; Joseph P McEvoy; Vicki G Davis; Donald C Goff; Henry A Nasrallah; Sonia M Davis; John K Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
Biological psychiatry 2009;66(11):1013-22.
2009: David L Penn; Richard S E Keefe; Sonia M Davis; Piper S Meyer; Diana O Perkins; Diane Losardo; Jeffrey A Lieberman
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
Schizophrenia research 2009;115(1):17-23.
2009: Robert A Rosenheck; Vicki G Davis; Sonia M Davis; Scott Stroup; Joseph McEvoy; Marvin Swartz; Jeffrey Lieberman
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
Schizophrenia research 2009;113(1):12-8.
2009: Lydia A Chwastiak; Robert A Rosenheck; Joseph P McEvoy; Thomas Stroup; Marvin S Swartz; Sonia M Davis; Jeffrey A Lieberman
The impact of obesity on health care costs among persons with schizophrenia.
General hospital psychiatry 2009;31(1):1-7.
2009: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Sonia M Davis; Marvin Swartz; Richard S E Keefe; Alexander Miller; Robert A Rosenheck; John K Hsiao
Results of phase 3 of the CATIE schizophrenia trial.
Schizophrenia research 2009;107(1):1-12.
2009: Robert A Rosenheck; Sonia M Davis; Nancy Covell; Susan Essock; Marvin Swartz; Scott Stroup; Joseph McEvoy; Jeffrey Lieberman
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
Schizophrenia research 2009;107(1):22-9.
2008: Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda Chakos; Marvin S Swartz; Richard S E Keefe; Thomas Stroup; Jeffrey A Lieberman
Extrapyramidal side-effects of antipsychotics in a randomised trial.
The British journal of psychiatry : the journal of mental science 2008;193(4):279-88.
2008: Gail L Daumit; Donald C Goff; Jonathan M Meyer; Vicki G Davis; Henry A Nasrallah; Joseph P McEvoy; Robert Rosenheck; Sonia M Davis; John K Hsiao; Thomas Stroup; Jeffrey A Lieberman
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
Schizophrenia research 2008;105(1-3):175-87.
2008: Jonathan M Meyer; Vicki G Davis; Joseph P McEvoy; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Gail L Daumit; John Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Schizophrenia research 2008;103(1-3):104-9.
2008: David L Sultzer; Sonia M Davis; Pierre N. Tariot; Karen S Dagerman; Barry D Lebowitz; Constantine G Lyketsos; Robert A Rosenheck; John K Hsiao; Jeffrey A Lieberman; Lon S Schneider
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
The American journal of psychiatry 2008;165(7):844-54.
2008: Marvin Swartz; Thomas Stroup; Joseph P McEvoy; Sonia M Davis; Robert A Rosenheck; Richard S E Keefe; John K Hsiao; Jeffrey A Lieberman
What CATIE found: results from the schizophrenia trial.
Psychiatric services (Washington, D.C.) 2008;59(5):500-6.
2008: Jonathan M Meyer; Vicki G Davis; Donald C Goff; Joseph P McEvoy; Henry A Nasrallah; Sonia M Davis; Robert A Rosenheck; Gail L Daumit; John Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
Schizophrenia research 2008;101(1-3):273-86.
2008: Sandra G Resnick; Robert A Rosenheck; Jose M Canive; Cyril De Souza; Thomas Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Jeffrey Lieberman
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
The journal of behavioral health services & research 2008;35(2):215-25.
2008: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Frederick W Reimherr; Del D Miller; Mark McGee; Ahsan Khan; Jose M Canive; Sonia M Davis; John K Hsiao; Jeffrey A Lieberman
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Schizophrenia research 2008;100(1-3):39-52.
2007: Robert A Rosenheck; Douglas L Leslie; Jody L Sindelar; Edward A Miller; Pierre N. Tariot; Karen S Dagerman; Sonia M Davis; Barry D Lebowitz; Peter V Rabins; John K Hsiao; Jeffery A Lieberman; Lon S Schneider
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
Archives of general psychiatry 2007;64(11):1259-68.
2007: Richard S E Keefe; Robert Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Archives of general psychiatry 2007;64(6):633-47.
2007: Marvin Swartz; Diana O Perkins; Thomas Stroup; Sonia M Davis; George Capuano; Robert A Rosenheck; Frederick W Reimherr; Mark F McGee; Richard S E Keefe; Joseph P McEvoy; John K Hsiao; Jeffrey A Lieberman
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
The American journal of psychiatry 2007;164(3):428-36.
2007: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; George Capuano; Robert A Rosenheck; Richard S E Keefe; Alexander Miller; Irving Belz; John K Hsiao
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
The American journal of psychiatry 2007;164(3):415-27.
2006: Susan M Essock; Nancy H Covell; Sonia M Davis; Thomas Stroup; Robert A Rosenheck; Jeffrey A Lieberman
Effectiveness of switching antipsychotic medications.
The American journal of psychiatry 2006;163(12):2090-5.
2006: Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; Thomas Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
The American journal of psychiatry 2006;163(12):2080-9.
2006: Lon S Schneider; Pierre N. Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; Thomas Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
The New England journal of medicine 2006;355(15):1525-38.
2006: Henry A Nasrallah; Jonathan M Meyer; Donald C Goff; Joseph P McEvoy; Sonia M Davis; Thomas Stroup; Jeffrey A Lieberman
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Schizophrenia research 2006;86(1-3):15-22.
2006: Richard S E Keefe; Robert Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):2033-46.
2006: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
The American journal of psychiatry 2006;163(4):611-22.
2006: Joseph P McEvoy; Jeffrey A Lieberman; Thomas Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
The American journal of psychiatry 2006;163(4):600-10.
2005: Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas Stroup; Sonia M Davis; Jeffrey A Lieberman
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
Schizophrenia research 2005;80(1):45-53.
2005: Scott Stroup; Paul Appelbaum; Marvin Swartz; Mukesh Patel; Sonia M Davis; Dilip V Jeste; Scott Y H Kim; Richard S E Keefe; Theo C Manschreck; Joseph McEvoy; Jeffrey Lieberman
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.
Schizophrenia research 2005;80(1):1-8.
2005: Del D Miller; Joseph P McEvoy; Sonia M Davis; Stanley N Caroff; Bruce L Saltz; Miranda Chakos; Marvin S Swartz; Richard S E Keefe; Robert A Rosenheck; Thomas Stroup; Jeffrey A Lieberman
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Schizophrenia research 2005;80(1):33-43.
2005: Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John K Hsiao; T Scott Stroup; Jeffrey A Lieberman
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Schizophrenia research 2005;80(1):19-32.
2005: Jonathan M Meyer; Henry A Nasrallah; Joseph P McEvoy; Donald C Goff; Sonia M Davis; Miranda Chakos; Jayendra K Patel; Richard S E Keefe; Thomas Stroup; Jeffrey A Lieberman
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Schizophrenia research 2005;80(1):9-18.
2005: Jeffrey A Lieberman; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne B Severe; John K Hsiao
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine 2005;353(12):1209-23.
2005: Mark Stork George; A John Rush; Lauren B Marangell; Harold A Sackeim; Stephen K Brannan; Sonia M Davis; Robert H Howland; Mitchel A Kling; Francisco Moreno; Barry R Rittberg; David L Dunner; Thomas Schwartz; Linda Carpenter; Michael Burke; Philip T Ninan; Paul Goodnick
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.
Biological psychiatry 2005;58(5):364-73.
2005: A John Rush; Harold A Sackeim; Lauren B Marangell; Mark Stork George; Stephen K Brannan; Sonia M Davis; Philip W Lavori; Robert H Howland; Mitchel A Kling; Barry R Rittberg; Linda Carpenter; Philip T Ninan; Francisco Moreno; Thomas Schwartz; Charles Conway; Michael Burke; John J Barry
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.
Biological psychiatry 2005;58(5):355-63.
2005: A John Rush; Lauren B Marangell; Harold A Sackeim; Mark Stork George; Stephen K Brannan; Sonia M Davis; Robert H Howland; Mitchel A Kling; Barry R Rittberg; William J Burke; Mark H Rapaport; John M Zajecka; Andrew A Nierenberg; Mustafa M Husain; David Ginsberg; Robert G Cooke
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
Biological psychiatry 2005;58(5):347-54.
2003: Sonia M Davis; Gary G Koch; Clarence E Davis; Lisa M LaVange
Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.
Schizophrenia bulletin 2003;29(1):73-80.
2003: Lon S Schneider; M Saleem Ismail; Karen S Dagerman; Sonia M Davis; Jason Olin; Dennis McManus; Eric Pfeiffer; J Michael Ryan; David L Sultzer; Pierre N. Tariot
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
Schizophrenia bulletin 2003;29(1):57-72.
2002: James H Kocsis; Alan F Schatzberg; A John Rush; Daniel N Klein; Robert H Howland; Leah Gniwesch; Sonia M Davis; Wilma Harrison
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo.
Archives of general psychiatry 2002;59(8):723-8.
2001: Lon S Schneider; Pierre N. Tariot; Constantine G Lyketsos; Karen S Dagerman; Kenneth L Davis; Sonia M Davis; John K Hsiao; D V Jeste; Ira R Katz; Jason T Olin; B G Pollock; Peter V Rabins; Robert A Rosenheck; Gary W Small; Barry D Lebowitz; Jeffrey A Lieberman
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2001;9(4):346-60.
2001: James M Russell; Lorrin M Koran; J Rush; Robert M A Hirschfeld; Wilma Harrison; Edward S Friedman; Sonia M Davis; M Keller
Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression.
Depression and anxiety 2001;13(1):18-27.
2000: Susan G Kornstein; Alan F Schatzberg; Michael E Thase; Kimberly A Yonkers; James P McCullough; Gabor I Keitner; Alan J Gelenberg; Christine E Ryan; A L Hess; Wilma Harrison; Sonia M Davis; Martin B Keller
Gender differences in chronic major and double depression.
Journal of affective disorders 2000;60(1):1-11.
2000: Susan G Kornstein; Alan F Schatzberg; Michael E Thase; Kimberly A Yonkers; James P McCullough; Gabor I Keitner; Alan J Gelenberg; Sonia M Davis; Wilma M Harrison; Martin B Keller
Gender differences in treatment response to sertraline versus imipramine in chronic depression.
The American journal of psychiatry 2000;157(9):1445-52.
2000: James P McCullough; Daniel N Klein; Martin B Keller; Charles Holzer; Sonia M Davis; Susan G Kornstein; Robert H Howland; Michael E Thase; Wilma M Harrison
Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction.
Journal of abnormal psychology 2000;109(3):419-27.
1998: Ivan W Miller; Gabor I Keitner; Alan F Schatzberg; Daniel N Klein; Michael E Thase; A John Rush; John Markowitz; D S Schlager; Susan G Kornstein; Sonia M Davis; Wilma M Harrison; Martin B Keller
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.
The Journal of clinical psychiatry 1998;59(11):608-19.
1998: Martin B Keller; Alan J Gelenberg; Robert M A Hirschfeld; A John Rush; Michael E Thase; James H Kocsis; John Markowitz; JA Fawcett; Lorrin M Koran; Daniel N Klein; James M Russell; Susan G Kornstein; James P McCullough; Sonia M Davis; Wilma M Harrison
The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.
The Journal of clinical psychiatry 1998;59(11):598-607.
1998: Gary G Koch; Sonia M Davis; R L Anderson
Methodological advances and plans for improving regulatory success for confirmatory studies.
Statistics in medicine 1998;17(15-16):1675-90.